Study on the Effect of Aprepitan on Chemotherapy-related Adverse Reactions of Gynecological Malignancies
DOI:
https://doi.org/10.62836/amr.v4i1.509Keywords:
arepitan, Chemotherapy for gynecological malignancies, adverse reactionsAbstract
Objective: To explore the clinical efficacy and safety of aprepitan in preventing chemotherapy-associated nausea and vomiting (CINV) in patients with gynecological malignancies. Methods: A total of 98 patients with gynecological malignant tumors in our hospital from January 2020 to December 2022 were selected and randomly divided into an observation group and a control group, with 49 cases in each group. The control rates of nausea and vomiting, symptom scores and adverse reactions were compared between the two groups. Results: The total score of R-INVR in the observation group was lower than that in the control group, the remission rate of nausea and vomiting and the total score of FLIE were higher than those in the control group (p < 0.001), and the incidences of adverse reactions such as fatigue, constipation, headache, diarrhea and anorexia were all lower than those in the control group (p < 0.05). Conclusion: Aprepitan can relieve nausea and vomiting caused by chemotherapy in patients with gynecological malignant tumors, and it has good safety. It is suitable for antiemetic management during chemotherapy in gynecological malignant tumors.
References
Chen Y. The Effect of Arepitan Capsules Combined with Palonosetron on Preventing Nausea and Vomiting Caused by Chemotherapy at Moderate to High Risk of Vomiting. Clinical Medical Practice 2025: 34(08): 597–600.
Tang R, Tian L. Cost-Effectiveness Analysis of Apirpitan Injection versus Fosapirpitan Injection in the Prevention of Nausea and Vomiting Caused by Hyperemetic Chemotherapy. Zhongnan Journal of Pharmacy 2025; 23(07): 2077–2082.
Wang F, Xia Y, Zhao Z, et al. Construction and Application of Evaluation Criteria for the Utilization of Apirpitan Capsules Based on Weighted TOPSIS Method. Practical Medicines and Clinical Practice 2025; 28(05): 337–343.
Zhang J, Fu L, Guo Q. Evaluation of the Efficacy and Economic Efficiency of Apirpitan in Preventing and Treating Nausea and Vomiting Caused by Platinum-Based Chemotherapy Drugs. Chinese Journal of Modern Pharmaceutical Application 2025; 19(09): 107–110.
Gu Q, Chen Z. Research Progress of Aprepitan in the Treatment of Nausea and Vomiting Caused by Chemotherapy for Tumors. Chinese Medical Sciences 2020; 10(19): 48–51.
Zhang Z. Observation on the Effect of Mirtazapine Combined with Palonosetron and Apirpitan in Preventing Nausea and Vomiting Caused by Hyperemetic Chemotherapy. Master’s Thesis, Xinxiang Medical University, Xinxiang, China, 2020.
Jiang Y, Song B. Clinical Observation on the Antiemetic Effect of Aprepitan in Platinum-Based Chemotherapy for Ovarian Malignant Tumors. Strait Pharmacy 2019; 31(12): 131–132.
Huang X, Mo L, Li X, et al. Meta-Analysis of the Impact of Aprepitan Triple Therapy on the Safety and Quality of Life of Patients with Malignant Tumors Undergoing Chemotherapy. Chinese Pharmacy 2018; 29(16): 2265–2272.
Zhang L. Analysis of the Efficacy of Apirpitan in Preventing Chemotherapy-Mediated Vomiting. Master’s Thesis, Tianjin Medical University, Tianjin, China, 2017.
Shi L, Wang L. Research Progress of NK-1 inhibitor Aprepitan in the Treatment of Chemotherapy-Induced Nausea and Vomiting. Heilongjiang Medical Sciences 2016; 39(06): 158–159.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Xiaojing Sun, Chan Liu, Hongyun Shi, Fei Teng, Wenfan Sun, Xinyue Zhang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivatives 4.0 International License.
